NEW YORK, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

NEW YORK, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz Jared Holz, Mizuho, ...

Health-care companies rose as traders rotated back into the sector amid optimism about blockbuster drugs. Novo Nordisk shares rose by more than 8% for one of their biggest gains in recent years after ...

On the winning side of Wall Street were Novo Nordisk’s U.S.-listed shares, which jumped 8.5%. The Danish company reported ...

The latest health briefs reveal Novo Nordisk's promising obesity treatment and a $7.4 billion Purdue Pharma settlement over ...

Here are some of the major companies whose stocks moved on the week’s news.

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

Novo Nordisk (NVO) has reportedly been criticized by a U.K. pharma industry group for mischaracterizing certain payments to ...

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.